Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data
September 17, 2015 10:09 AM EDTCanaccord Genuity reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), and raised the price target to $44.00 (from $40.00), following announced Rocket 2 data. It's clear that the drug has clinically meaningful activity in glaucoma and in Canaccord's opinion is very approvable.
Analyst Corey Davis commented,... More
RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 Data
September 17, 2015 9:00 AM EDTRBC Capital lifts its price target on Outperform-rated Aerie Pharmaceuticals (Nasdaq: AERI) from $31 up to $44 following news that Rhopressa Phase 3 met its primary endpoint.
Analyst Michael J. Yee noted the following key points:
Safety is in-line and not too different from Rocket 1. Hyperemia is a known side effect and it was higher in the BID than the QD arm; however, of the 35% with increased redness, 83% scored as mild... MoreAerie Pharma (AERI) PT Raised to $40 at Cantor Fitzgerald
September 17, 2015 7:24 AM EDTCantor Fitzgerald analyst Caroline Corner reiterated a Buy rating and boosted her price target on Aerie Pharma (NASDAQ: AERI) to $40.00 (from $30.00) after the company announced positive results from the Rhopressa Phase III Rocket 2 trial.
Corner commented, "We are pleased to see this... More
Aerie Pharma (AERI) PT Raised to $48 at Brean Capital
September 17, 2015 6:59 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $48.00 (from $33.00), saying Rocket 2 is positive for Rhopressa.
Yang commented, "While approvals on Rhopressa and Roclatan are not expected until the 2017-2018 time... More
Aerie Pharma (AERI) PT Raised to $45 at Needham & Company
September 17, 2015 6:22 AM EDTNeedham & Company analyst Serge Belanger reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $45.00 (from $27.00) after the company reported top-line results from ROCKET-2, where Rhopressa met the primary endpoint by demonstrating non-inferiority in IOP-lowering vs. timolol.
Belanger... More
Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy Endpoint
September 16, 2015 4:04 PM EDTAerie Pharma (NASDAQ: AERI) reported the successful results of its second Phase 3 trial for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa compared to timolol, the most widely used comparator. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.
Rhopressa Phase 3 Highlights for Rocket 2
Rhopressa, dosed both once-daily and twice-daily, achieved its primary... More